TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01585636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: Single oral dose
Study: NCT02039960

Intervention type: DRUG
Intervention: Bupropion
Description: Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.

Intervention type: DRUG
Intervention: Bupropion
Description: Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.

Intervention type: DRUG
Intervention: Bupropion
Description: Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.
Study: NCT04157140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TACE+RFA
Description: TACE first, followed by RFA within day7（+/-3days）
Study: NCT00991263

Intervention type: GENETIC
Intervention: gene expression analysis

Intervention type: GENETIC
Intervention: polymerase chain reaction

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT02491268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00565942

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Integrative care
Description: In short, integrative care was up to 10 complementary therapy treatments delivered to the patient in addition to the usual care over an intervention period of up to 12 weeks. The integrative care was provided by a multidisciplinary team coordinated by a gate keeping general practitioner with clinical knowledge and experience of CTs and senior licensed/certified CT providers representing Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The usual care treatment was coordinated by the patient's general practitioner and complied with the clinical practice routines at the participating primary care units. Conventional procedures included but were not exclusive to advice, prescription of drugs, sick leave and physiotherapy/physical therapy. There were no constraints to the provided usual care as the study aimed to pragmatically reflect the general practitioners' standard care and treatment as usual.
Study: NCT02469896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: IV Infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Infusion
Study: NCT04174456

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG PET
Description: baseline and 6-month follow-up FDG PET

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FDG PET
Description: baseline and 6-month follow-up FDG PET
Study: NCT03196986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mil60
Description: 15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then switched to mil60 at 7.5mg/kg
Study: NCT03015792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01136811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer assisted surgery
Description: use of computer assisted surgical device in vascular surgery~completion of the proximal (femoral) anastomosis portion of a lower extremity bypass procedure
Study: NCT02441062

Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-DOTATOC PET/CT
Description: Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors
Study: NCT02113384

Intervention type: OTHER
Intervention: Observational study.
Description: Biobanking of tissue (tumor biopsy, peritoneal lavage, blood specimen) from patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
Study: NCT05429333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-assisted personalized diet
Description: The AI-based nutritional recommendations system is based on the eating rates of the individual in a certain period, to ensure the homeostasis of the microbiome and increase the microbial diversity.~After the microbiome analysis reports of the study group are released, a 6-week diet was designed regarding AI-based food scores specific to constipated individuals in accordance with the individual's lifestyle and comorbidities. Diet lists are updated according to the individual's feedback, recovery level, and wishes with weekly meetings.
Study: NCT03015441

Intervention type: OTHER
Group type: OTHER
Intervention: Milk product fermented by lactic bacteria or not fermented
Description: 2 pots of 125g consumed daily during 28 days

Intervention type: OTHER
Group type: OTHER
Intervention: Milk product fermented by lactic bacteria or not fermented
Description: 2 pots of 125g consumed daily during 28 days
Study: NCT04254185

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple decompression
Description: Surgical technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous anterior transposition
Description: Surgical technique
Study: NCT01068353

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: 50 mg given as a once weekly subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection given once weekly
Study: NCT01375361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: 2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
Study: NCT03717831

Intervention type: OTHER
Intervention: Observational study of standard of care
Description: Observational cohort study

Intervention type: OTHER
Intervention: Observational study of standard of care
Description: Observational cohort study
Study: NCT03199937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexible Futures
Description: Flexible Futures is a novel and innovative cognitive-behavioral treatment that directly addresses executive function and self-regulation deficits in ASD. Flexible futures targets flexibility and planning through self-regulatory scripts that are consistently modeled and reinforced. Scripts compensate for the inner speech and organization/integration deficits in ASD, and are practiced repeatedly to achieve automaticity. Content focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, self-advocacy skills application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current standard of care
Description: Flexible Futures will be compared to a social skills treatment as usual that capitalizes on current standard of care provided by local school districts.
Study: NCT03753633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech therapy
Description: Oropharyngeal exercises will be performed under the supervision of a speech therapist.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Inspiratory and expiratory exercises recruiting diaphragmatic muscles
Study: NCT03537950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLC
Description: Single oral dose of PLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLC
Description: Single oral dose of PLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLC
Description: Single oral dose of PLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLC
Description: Single oral dose of PLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLC
Description: Single oral dose of PLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLC
Description: Single oral dose of PLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Single oral dose of cannabidiol (CBD) - 600mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Single oral dose of cannabidiol (CBD) - 600mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Single oral dose of cannabidiol (CBD) - 600mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Single oral dose of cannabidiol (CBD) - 600mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Single oral dose of cannabidiol (CBD) - 600mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Single oral dose of cannabidiol (CBD) - 600mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBDV
Description: Single oral dose of cannabidivarin (CBDV) - 600mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBDV
Description: Single oral dose of cannabidivarin (CBDV) - 600mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBDV
Description: Single oral dose of cannabidivarin (CBDV) - 600mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBDV
Description: Single oral dose of cannabidivarin (CBDV) - 600mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBDV
Description: Single oral dose of cannabidivarin (CBDV) - 600mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBDV
Description: Single oral dose of cannabidivarin (CBDV) - 600mg.
Study: NCT03844490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CESSATION OF CORD PULSE
Description: In this group the umbilical cord will remain unclamped until the spontanous pulsation stops.~At this time, cord clamping will be made.

Intervention type: OTHER
Group type: OTHER
Intervention: CONTROL
Description: In this group management will be carried out as usual routine (cord clamping from one to three minutes after delivey)
Study: NCT01217268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training in person centered care by supervision using video-conference
Description: The investigators will use video-conference for supervising and training of staff members in nursing homes
Study: NCT00366704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bifeprunox
Description: .25mg titrate up to 20mg/day (week 1) then 30mg/day (weeks 2-8)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: 4mg, QD, 8 week treatment
Study: NCT03197363

Intervention type: OTHER
Intervention: Discovering novel risk factors.
Description: The study protocol includes multiple imaging and functional investigations (including heart, carotid, thyroid, liver ultrasound, fundoscopy, plethysmography, pulse wave velocity, ankle-brachial index, ECG, body composition measured by bioimpedance and dual energy x-ray absorptiometry, anthropometric assessment, rhinometry, hand grip test, oral glucose tolerance test, advance glycation end-products measurement, voice recording. There will be a detailed and verified questionnaires concerning various activities of the subject: physical activity, depression, sino-nasal symptoms, prostate hypertrophy, female urinary tract symptoms, quality of life, smoking and drinking addiction, hirsutism.
Study: NCT01759212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cells implantation
Study: NCT00542529

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Imprime PGG TM for Injection
Description: Doses of 2.0 and 4.0 mg/kg intravenous Imprime PGG administered over 1-2 hr for up to 4 consecutive days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Imprime PGG TM for Injection
Description: Doses of 2.0 and 4.0 mg/kg intravenous Imprime PGG administered over 1-2 hr for up to 4 consecutive days
Study: NCT00504010

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arnica Montana
Description: Applied to lower extremity once a day for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo cream
Description: placebo cream applied to leg daily for 3 days
Study: NCT00106522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25mg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10-25mg weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: 10-25mg weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 4mg/kg iv every 4 weeks
Study: NCT01350453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeCIT
Description: Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Participants will receive their usual care from their NHS provider.
Study: NCT03602456

Intervention type: OTHER
Intervention: Kentucky HEALTH
Description: KY HEALTH is the modified Medicaid program including key components such as community engagement requirements, premiums and lockouts, redetermination lockouts, and the My Rewards incentive program.
Study: NCT04025463

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HHMB
Description: Blended, culturally-congruent, evidence-informed care model to increase patient and clinic participation in CVD risk reduction for patients with HIV
Study: NCT01567982

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS, prefrontal cortex and parietal cortex
Description: tDCS is a non invasive brain stimulation methods. We will use two anodes to stimulate prefrontal and/or parietal cortex using 2mA current for 20 minutes.
Study: NCT01482663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Skin Clinic
Description: The intervention is founded upon three concurrent elements. Firstly, a SKIN-profile generated by data from a baseline questionnaire (S=Susceptibility, K=Competencies, I=Individual characteristics, N=Necessary precautions).~Secondly, a patient self-management book which includes a patient's log and is offered in both an online and a physical form. Also support to self-management is offered through possible asynchronous communication and networking.~Finally, a counselling consultation with a nurse, trained within dermatology.
Study: NCT00185250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Description: 2 MIU per application in week 1 and 4 MIU per application in weeks 2 to 24 given subcutaneously every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)
Description: 2 MIU per application in week 1, 4 MIU per application in weeks 2 to 3 and 8 MIU per application in weeks 4 to 24 given subcutaneously every other day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.25 ml in week 1 and 0.50 ml in weeks 2 to 24 given subcutaneously every other day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.25 ml in week 1, 0.50 ml in weeks 2 to 3 and 1.00 ml in weeks 4 to 24 given subcutaneously every other day
Study: NCT04354805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Description: (Oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days)
Study: NCT02880202

Intervention type: OTHER
Group type: OTHER
Intervention: Massage Therapy
Description: The massage therapy is provided by certified massage therapists and delivered in the home setting. Techniques and duration of massage therapy is customized based on input from the patient and/or caregiver at the start of the session regarding nature and location of discomfort and other symptoms, and based on other factors such as contra-indications/complicating factors, medical issues, and additional diagnoses. The number of massage therapy interventions range from 2-3, 1 week apart, with each session lasting between 20-45 minutes in duration.
Study: NCT04702282

Intervention type: DIAGNOSTIC_TEST
Intervention: ropivacain concentration measurements
Description: Free and total plasma concentrations of ropivacaine were measured within 24 hours using liquid chromatography - mass spectrometry. A population pharmacokinetic model was built using non-linear mixed effect models

Intervention type: DIAGNOSTIC_TEST
Intervention: ropivacain concentration measurements
Description: Free and total plasma concentrations of ropivacaine were measured within 24 hours using liquid chromatography - mass spectrometry. A population pharmacokinetic model was built using non-linear mixed effect models
Study: NCT01936142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of RenalGuard
Study: NCT01884233

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care will include usual treatment for HIV and a pamphlet that will be provided to the participants with information about ART adherence and relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard care will include usual treatment for HIV and a pamphlet that will be provided to the participants with information about ART adherence and relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging CBT (TXT-CBT)
Description: Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
Study: NCT01052688

Intervention type: OTHER
Intervention: Maternal blood draw of 30 to 50ml
Description: Maternal blood draw of 30 to 50mls during pregnancy. Blood may be drawn up to 5 times during the pregnancy between weeks 8 and 36 gestation.
Study: NCT02484339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride
Description: Arm A: EBRT and timely sequential start with Radium-223 dichloride 55 kBq/kgbw (6 i.v. injections every 4 weeks) and best supportive care until progression or intolerable toxicity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional or high dose radiotherapy
Description: Arm B: External beam radiotherapy (EBRT)-\>-\>conventional or high dose radiotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional or high dose radiotherapy
Description: Arm B: External beam radiotherapy (EBRT)-\>-\>conventional or high dose radiotherapy
Study: NCT01868139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liquid nitrogen spray cryotherapy with the truFreeze device
Description: Low-pressure liquid nitrogen is sprayed through an upper endoscope on the diseased esophageal tissue to freeze and destroy it. The upper endoscope enables direct visualization of mucosal freeze during spray of the liquid nitrogen onto the mucosa and avoids the need for direct contact with the tissues. The target area is frozen and thawed for several consecutive cycles. The treated tissue becomes necrotic and sloughs, with new, healthy tissue regenerating in its place.
Study: NCT04657757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoral apparatus
Description: Eight platelets with different material composition and surface properties are fastened in a holder (carrier rondell) with 15 mm diameter and inserted into the braces. Braces are to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures. Platelets then are removed and analyzed. After a first course the braces are to be cleaned in chlorhexidine solution in an ultrasonic bath; followed by a second identical course (Braces to be worn for 28 hours in the oral cavity except for meals and oral hygiene procedures).
Study: NCT02423239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexanabinol
Description: Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Patients will receive Sorafenib at a dose of 400 mg bid (oral administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Patients will receive Nab-paclitaxel at a dose of 125mg/m2 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive Gemcitabine at a dose of 1000mg/m2 intravenous infusion